Arkolith/Insider Trading/KROS/Form 4

Seehra Jasbir

CHIEF EXECUTIVE OFFICER, DirectorKeros Therapeutics, Inc. (KROS) · full profile →Form 4 · filed Apr 7, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 4, 2025Option exercise(M)49K$0.30$15K302K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 4, 2025Option exercise(M)49K—$0252K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-010290) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML